|
|
|
 |
Biomarker Services |
|
| |
Proven Experience, Broad Expertise, Rapid Development
|
Cambridge Biomedical is the perfect partner for biomarker assay development. Founded in 1997, Cambridge Biomedical has a proven track record of successfully developing and validating analytical methods in a CLIA/CAP environment under FDA compliance. Cambridge Biomedical's broad experience with a variety of technologies makes it a cost effective resource in the expeditious assay development and commercialization process.
Whether you are developing biomarker assays for use in clinical trials, post-approval diagnostics/prognostics, or even phase four pharmacovigilance, Cambridge Biomedical can help you quickly meet your goals. We work with large molecules, biologics and medical devices and handle a wide range of projects; from de novo test development to technology transfer engagements where partners already have the target and reagents but require feasibility and assay validation.
Unlike at many large companies where individual projects can get lost in the shuffle, every project is important to us. Cambridge Biomedical has the right size, technical breadth and depth, and the corporate commitment to ensure your project receives the focus and attention it needs to be successful.
Cambridge Biomedical is CLIA certified, CAP accredited, and provides services that support best laboratory practices and GLP compliance. We help our clients navigate through quality and regulatory requirements from preclinical to IV studies.
|
| |
|
|
| |
|
|
 |
CRO SERVICES
"Very good technically. People clearly knew what they were doing - knew how to handle assays, data management."
Pharmaceutical Clinical Trial Manager |
|
|
|
|
|
|
|
|
